Patient Experiences with the Impacts of Multiple Sclerosis & Disease-Modifying Therapies

Bari Talente,¹ Lisbet T Finseth,¹ Natalie Blake,² Kathleen Costello,³ Hollie Schmidt,⁴ Joe Vandigo,⁵ Elisabeth M Oehrlein<sup>5

1</sup>National Multiple Sclerosis Society, Washington, DC, USA; ²Multiple Sclerosis Foundation, Fort Lauderdale, FL, USA; ³Can Do Multiple Sclerosis, Avon, CO, USA; ⁴Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, USA; ⁵Applied Patient Experience, Washington, DC, USA

Correspondence: Joe Vandigo, Applied Patient Experience, Washington, DC, USA, Email jvandigo@appliedpx.com Bari Talente, National Multiple Sclerosis Society, Washington, DC, USA, Email bari.talente@nmss.org

Purpose: Disease-modifying therapies (DMTs) are vital for managing multiple sclerosis (MS), but research using administrative data often excludes patient preferences and factors clinicians consider in treatment decisions. Patient experience data are crucial to understand and improve MS treatment initiation, adherence, and outcomes.